Trade CNS Pharmaceuticals, Inc. - CNSP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0073 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.9501 |
| Open | 0.9196 |
| 1-Year Change | 289.66% |
| Day's Range | 0.862 - 0.9216 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2025 | 0.9501 | -0.2195 | -18.77% | 1.1696 | 1.1796 | 0.9047 |
| Apr 14, 2025 | 1.2796 | -0.0300 | -2.29% | 1.3096 | 1.3296 | 1.1796 |
| Apr 11, 2025 | 1.3196 | 0.1400 | 11.87% | 1.1796 | 1.3596 | 1.1096 |
| Apr 10, 2025 | 1.1796 | 0.0900 | 8.26% | 1.0896 | 1.1896 | 1.0096 |
| Apr 9, 2025 | 1.1196 | 0.0900 | 8.74% | 1.0296 | 1.1196 | 0.9993 |
| Apr 8, 2025 | 1.0196 | -0.1200 | -10.53% | 1.1396 | 1.1396 | 0.9996 |
| Apr 7, 2025 | 1.1096 | 0.0600 | 5.72% | 1.0496 | 1.1196 | 0.9672 |
| Apr 4, 2025 | 1.0696 | 0.0300 | 2.89% | 1.0396 | 1.1296 | 0.9996 |
| Apr 3, 2025 | 1.1296 | -0.1000 | -8.13% | 1.2296 | 1.2296 | 1.0996 |
| Apr 2, 2025 | 1.2296 | -0.0200 | -1.60% | 1.2496 | 1.3096 | 1.2196 |
| Apr 1, 2025 | 1.2796 | 0.0000 | 0.00% | 1.2796 | 1.4496 | 1.2696 |
| Mar 31, 2025 | 1.3596 | 0.1600 | 13.34% | 1.1996 | 1.3596 | 1.1996 |
| Mar 28, 2025 | 1.2696 | -0.0300 | -2.31% | 1.2996 | 1.3396 | 1.1996 |
| Mar 27, 2025 | 1.2996 | -0.0800 | -5.80% | 1.3796 | 1.4896 | 1.2696 |
| Mar 26, 2025 | 1.4296 | -0.1300 | -8.34% | 1.5596 | 1.5796 | 1.3596 |
| Mar 25, 2025 | 1.6096 | 0.1600 | 11.04% | 1.4496 | 1.6396 | 1.2696 |
| Mar 24, 2025 | 3.3496 | -0.3200 | -8.72% | 3.6696 | 3.7096 | 3.1496 |
| Mar 21, 2025 | 3.6796 | 0.2500 | 7.29% | 3.4296 | 3.7996 | 3.4196 |
| Mar 20, 2025 | 3.5996 | -0.1400 | -3.74% | 3.7396 | 3.7996 | 3.3396 |
| Mar 19, 2025 | 3.7896 | 0.0500 | 1.34% | 3.7396 | 4.5796 | 3.7296 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CNS Pharmaceuticals, Inc. Company profile
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals Inc. is a clinical pharmaceutical company. The Company is focused on development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The Company is developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 48% to $14M. Higher net loss reflects Research and development increase of 85% to $9.3M (expense), Selling/General/Admin Expense increase of 7% to $4.7M (expense), Interest expense increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.57 to -$0.53.
| Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com